Theravance Biopharma (NASDAQ:TBPH) Raised to “Strong-Buy” at Wall Street Zen

Theravance Biopharma (NASDAQ:TBPH) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Sunday.

A number of other equities analysts have also recently commented on the stock. BTIG Research reaffirmed a “buy” rating and set a $21.00 price objective on shares of Theravance Biopharma in a research report on Friday, March 20th. HC Wainwright increased their price objective on shares of Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Weiss Ratings upgraded shares of Theravance Biopharma from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday. TD Cowen lifted their target price on shares of Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, March 23rd. Finally, B. Riley Financial reiterated a “neutral” rating and issued a $14.00 price target (down from $28.00) on shares of Theravance Biopharma in a research note on Wednesday, March 4th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Theravance Biopharma currently has an average rating of “Moderate Buy” and a consensus price target of $21.33.

Theravance Biopharma Trading Down 0.7%

TBPH stock opened at $15.08 on Friday. Theravance Biopharma has a 1-year low of $7.90 and a 1-year high of $21.03. The business’s 50 day simple moving average is $17.49 and its 200 day simple moving average is $16.91. The firm has a market capitalization of $776.47 million, a PE ratio of 7.43 and a beta of 0.17.

Insider Buying and Selling

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the transaction, the senior vice president owned 232,699 shares in the company, valued at $3,248,478.04. This trade represents a 11.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Theravance Biopharma

Institutional investors and hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. lifted its position in Theravance Biopharma by 26.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 515 shares during the period. Tower Research Capital LLC TRC lifted its stake in Theravance Biopharma by 18.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 781 shares during the last quarter. Creative Planning raised its holdings in shares of Theravance Biopharma by 6.7% during the 3rd quarter. Creative Planning now owns 13,450 shares of the biopharmaceutical company’s stock worth $196,000 after buying an additional 842 shares in the last quarter. State of Wyoming boosted its stake in Theravance Biopharma by 5.7% in the second quarter. State of Wyoming now owns 18,928 shares of the biopharmaceutical company’s stock valued at $209,000 after buying an additional 1,019 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in Theravance Biopharma by 6.9% during the second quarter. The Manufacturers Life Insurance Company now owns 15,747 shares of the biopharmaceutical company’s stock worth $174,000 after acquiring an additional 1,020 shares in the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.